Technical Analysis for CGEN - Compugen Ltd.
|Grade||Last Price||% Change||Price Change|
CGEN closed up 0.96 percent on Friday, January 18, 2019, on 65 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Down||Up||Up|
|See historical CGEN trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Overbought Stochastic||Strength||0.00%|
|Jan 18||Up 3 Days in a Row||Strength||0.00%|
|Jan 18||Up 4 Days in a Row||Strength||0.00%|
|Jan 17||50 DMA Support||Bullish||0.96%|
|Jan 17||MACD Bullish Centerline Cross||Bullish||0.96%|
|Jan 17||Wide Bands||Range Expansion||0.96%|
|Jan 17||Overbought Stochastic||Strength||0.96%|
|Jan 17||Up 3 Days in a Row||Strength||0.96%|
|Jan 16||Crossed Above 50 DMA||Bullish||6.02%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CGEN news...
|52 Week High||5.0|
|52 Week Low||2.0|
|200-Day Moving Average||3.4179|
|50-Day Moving Average||2.9855|
|20-Day Moving Average||2.627|
|10-Day Moving Average||2.899|
|Average True Range||0.2031|
|Chandelier Exit (Long, 3 ATRs )||2.5707|
|Chandelier Exit (Short, 3 ATRs )||2.6093|
|Upper Bollinger Band||3.2508|
|Lower Bollinger Band||2.0032|
|Percent B (%b)||0.94|
|MACD Signal Line||-0.0512|
|Market Cap||162.09 Million|
|Num Shares||51.1 Million|
|Price-to-Earnings (P/E) Ratio||-4.73|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||3.34|
|Resistance 3 (R3)||3.32||3.25||3.31|
|Resistance 2 (R2)||3.25||3.21||3.26||3.30|
|Resistance 1 (R1)||3.21||3.18||3.23||3.23||3.29|
|Support 1 (S1)||3.10||3.10||3.12||3.12||3.05|
|Support 2 (S2)||3.03||3.07||3.04||3.04|
|Support 3 (S3)||2.99||3.03||3.03|
|Support 4 (S4)||3.01|